Cagrilintide + Semaglutide

Cagrilintide + Semaglutide

Cagrilintide + Semaglutide is a two-component research blend of a long-acting amylin analog (cagrilintide) and a GLP-1 receptor agonist (semaglutide). The labeled presentation on this sheet is 5 mg + 5 mg. This listing is for laboratory research use only. It is not a drug, food, cosmetic, or dietary supplement, and it is not approved for human or veterinary use.

Research Context

Cagrilintide appears in the scientific literature as an amylin-receptor (calcitonin receptor / RAMP) agonist; semaglutide appears as an acylated GLP-1 analog. Combination programs have examined the two pathways together. This listing is the 5+5 research blend, not a drug product. This page does not describe administration, dosing, or personal use.

Research Overview

Published work has examined concurrent amylin-pathway and GLP-1-pathway signaling in metabolic experimental systems. Findings from those models are not established as safe or effective for people or animals, and nothing here is medical advice.

Key Research Focus Areas

• Two-component identity: long-acting amylin analog + GLP-1 analog
• Amylin (CTR/RAMP) and GLP-1 receptor signaling
• Combination incretin–amylin laboratory models
• Analytical identity of a 5+5 research blend

Important Disclaimer

For research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease. Not medical advice. Handle only in a qualified research setting and in compliance with applicable law.